Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Prescriber Training: US FDA Still Debating Mandate; CMS Policies Having Impact Now

Executive Summary

Even after convening a two-day meeting with speakers from across the health care sector to discuss how opioid prescriber education can be improved, FDA doesn’t seem any closer to determining how to mandate training – but there are some reasons to be optimistic about a 'culture' change nevertheless.

You may also be interested in...



FDA's Opioid Programs: After Training, What's The Next Step?

Treatment guidelines may also appear in opioid labeling, and insurers seem to be taking the agency's advice, but will it be enough to satisfy Congress?

White House Opioid Report Urges Better Access To Overdose Treatment; Mandatory Prescriber Education

Pricing of anti-addiction therapies could come under more pressure from HHS if Trump Administration accepts White House commission recommendation to declare public health emergency on opioid crisis.

Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?

Appropriations bill report includes language stating that it is 'imperative' the agency take all steps necessary to require opioid prescriber training.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel